Clinical Trial Update: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HLX04-O versus Ranibizumab in wet age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• HLX04-O
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Age Related Macular Degeneration | Phase 3 | Status: COMPLETED